How the LOT Network seeks to protect medtech, biopharma IP

There are about 30,000 to 40,000 patents for sale on the open market at any moment. Traditionally, most patents for sale stem from distressed tech companies.

Patent assertion entities (PAEs, sometimes referred to as “patent trolls”) take advantage of the situation by buying up patents that provide fodder for patent lawsuits.

“They can just find a halfway decent looking patent for $50,000 or $100,000, and then they can threaten a high tech company with a $100 million lawsuit,” said Ken Seddon, CEO of the nonprofit LOT Network focused on protecting companies from the threat of PAE litigation.

Get the full story form our sister site, Drug Discovery & Development. 

Read more
  • 0

Design patents can provide extra protection for medical robots

Filing design patents can protect a medical robot’s overall aesthetic and the software user interface.

Roman Fayerberg, Todd C. Basile and David J. Dykeman, Greenberg Traurig

[Image from Pixabay]Medical robotics companies often emphasize utility patents when building strategic patent portfolios, given the complex nature of robotics technology. However, don’t overlook design patents, which provide another layer of protection by covering elements of robotics beyond the scope of utility patents.

A robust patent portfolio is an important indicator of a successful medical robotics company. As the medical robotics industry continues to grow and more and more companies enter the increasingly competitive market, a medical robotics company needs a comprehensive and strategic patent portfolio around its technology to compete. A strategic patent portfolio attracts investors, keeps competitors at bay, and provides necessary ammunition in litigation.

Go to our sister si…

Read more
  • 0

Design patents can provide extra protection for medical robots

Filing design patents can protect a medical robot’s overall aesthetic and the software user interface.

Roman Fayerberg, Todd C. Basile and David J. Dykeman, Greenberg Traurig

[Image from Pixabay]

Medical robotics companies often emphasize utility patents when building strategic patent portfolios, given the complex nature of robotics technology. However, don’t overlook design patents, which provide another layer of protection by covering elements of robotics beyond the scope of utility patents.

A robust patent portfolio is an important indicator of a successful medical robotics company. As the medical robotics industry continues to grow and more and more companies enter the increasingly competitive market, a medical robotics company needs a comprehensive and strategic patent portfolio around its technology to compete. A strategic patent portfolio attracts investors, keeps competitors at bay, and provides …

Read more
  • 0

Keys to protecting your medtech AI from competitors

AI is a hot area in medtech.  A panel of intellectual property experts had advice on protecting the IP.

DeviceTalks

[Image from Pixabay]

Between 2002 and 2019, annual AI patent applications more than doubled, and AI patent applications increased from 9% of all patent applications to 16%. AI is a white-hot area for investment and creation of valuable intellectual property, including artificial intelligence related to medical devices.

Protecting medical device-related AI was the topic of a recent episode of MassDevice and Medical Design & Outsourcing’s DeviceTalks Tuesdays, sponsored by Finnegan, a law firm that handles all aspects of IP.

The discussion involved Anthony Del Monaco and Cecilia Sanabria, both partners at Finnegan, and two CEOs of healthcare companies that have developed exciting AI-related IP: Jan De Backer, CEO of Fluidda, a respiratory imaging company, and Todd Usen, CEO o…

Read more
  • 0

CoorsTek scores EU legal win in pink components trademark dispute

CoorsTek CeraSurf-p ceramic components for total hip arthroplasty [Image courtesy of CoorsTek]

The EU Trademark Court of Appeals in Paris recently upheld a Paris EU Trademark High Court decision that sided with CoorsTek against CeramTec in a trademark dispute over “pink” ceramic hip components.

The Paris Court of Appeals in its June 2021 ruling upheld the cancelations of the three EU trademarks and the dismissal of CeramTec’s trademark infringement and parasitic competition claims against CoorsTek — confirming the finding that CeramTec filed the trademarks in bad faith. While dismissing CoorTek’s counterclaim against CeramTec, the court also ordered CeramTec to pay CoorTek €50,000 in damages.

“CoorsTek is extremely pleased with the latest decision by the EU Trademark Court of Appeals,” CoorsTek CEO Jonathan Coors said in a July 15 news release. “Competition drives innovation, and patien…

Read more
  • 0

SCOTUS preserves assignor estoppel in Minerva Surgical v. Hologic patent case

The front of U.S. Supreme Court in Washington, D.C. (Adobe stock photo)

The U.S. Supreme Court, in its Minerva Surgical v. Hologic ruling today preserved the legal doctrine of assignor estoppel — that inventors who sell patent rights can’t turn around and sue over the validity of the patents.

However, Justice Elena Kagan, in her opinion for the majority, did say that the doctrine has limits.

Get the full story on our sister site Medical Design & Outsourcing. 

Read more
  • 0

SCOTUS preserves assignor estoppel in Minerva Surgical v. Hologic patent case

The front of U.S. Supreme Court in Washington, D.C. [Adobe stock photo]

The U.S. Supreme Court, in its Minerva Surgical v. Hologic ruling today preserved the legal doctrine of assignor estoppel — that inventors who sell patent rights can’t turn around and sue over the validity of the patents.

However, Justice Elena Kagan, in her opinion for the majority, did say that the doctrine has limits.

The convoluted case involves the NovaSure system for abnormal uterine bleeding that Csaba Truckai invented in the late 1990s, filing for a patent assigned to his company Novacept. Hologic eventually acquired Novacept in 2007 and got claims added to the patent in 2015. Months later, Hologic sued Minerva Surgical — the new company Truckai had founded — for patent infringement. Minerva Surgical makes the Minerva Endometrial Ablation System, touted as an improved device to treat abnormal uterine bleeding.

In…

Read more
  • 0

Answering the CDMO shortage: A new paradigm for drug development

Photo by Isaac Quesada on Unsplash

What can the pharma industry do about the critical shortage of contract manufacturing organization (CMO) and contract development and manufacturing company (CDMO) facilities?

For a growing number of young entrepreneurial drug companies, the answer is a middle ground between building their own facilities and outsourcing to the saturated CMO/CDMO market. This middle ground lies in hybrid flexible cleanroom facilities with wraparound support services, which are gaining greater acceptance in the pharma industry. This model allows companies to leverage their manufacturing expertise while still maintaining control of their intellectual property. This approach is particularly valuable as new therapeutic technologies emerge, which require a different competency than many of the existing CMO/CDMO facilities can handle. Hybrid flexible cleanroom facilities are likely to emerge as a n…

Read more
  • 0

3 ways to a strategic medtech patent portfolio

[Photo by Hassan Pasha on Unsplash]Protecting innovations leads to medtech success. Top Greenberg Traurig patent attorneys explain how.

Roman Fayerberg and David J. Dykeman, Greenberg Traurig

A strategic patent portfolio is key to a medtech company’s growth and success, but building a robust patent portfolio takes strategy, time and money.

While there are no shortcuts to building a strategic patent portfolio, there are several ways medtech companies can get a head start on the competition.

Go to the MassDevice sister site Medical Design & Outsourcing to discover some of the strategies. 

Read more
  • 0

3 ways to a strategic medtech patent portfolio

[Photo by Hassan Pasha on Unsplash]

Protecting innovations leads to medtech success. Top Greenberg Traurig patent attorneys explain how.

Roman Fayerberg and David J. Dykeman, Greenberg Traurig

A strategic patent portfolio is key to a medtech company’s growth and success, but building a robust patent portfolio takes strategy, time and money.

While there are no shortcuts to building a strategic patent portfolio, there are several ways medtech companies can get a head start on the competition.

1. Establish processes to identify and protect inventions

Early-stage medtech companies should implement in-house processes and procedures to capture and protect innovations in a strategic manner.

Many large medtech companies employ experienced in-house patent attorneys whose primary responsibility is building and managing their company’s patent portfolio. Without in-house patent attorneys, these …

Read more
  • 0

Pharma researcher charged with theft of trade secrets  

Image from Bill Oxford via Unsplash

A former director of medical and scientific affairs at Merck (NYSE:MRK) faces criminal charges in federal court in New Jersey for allegedly stealing and transmitting trade secrets.

Shafat A. Quadri has been released on $100,000 unsecured bond. He was most recently employed at AstraZeneca (NSDQ:AZN).

The single count of trade secret theft carries a maximum potential penalty of up to 10 years in prison and a fine as high as $250,000, or double the total financial gain or loss, according to Rachael A. Honig, acting U.S. attorney for the District of New Jersey.

The complaint describes Quadri’s former employer as “Company 1,” stating that the organization reached out to the FBI in Oct. 2019 to report suspicious activity regarding its sensitive intellectual property. Quadri had been employed at that company until Sept. 30, 2019.

The suit alleges that Quadri …

Read more
  • 0

Hackers targeted pharma and other IP for Chinese government, indictment claims

A federal grand jury in Spokane, Wash. has indicted two Chinese nationals on charges that they hacked into pharma companies and hundreds of other businesses, governments and organizations — in some cases on behalf of the Chinese Ministry of State Security.

The 11-count indictment, which the U.S. Department of Justice announced today, alleges that Li Xiaoyu and Dong Jiazhi for the past 10 years targeted companies in countries with high technology industries, including the United States. They stole terabytes of data.

“China has now taken its place, alongside Russia, Iran and North Korea, in that shameful club of nations that provide a safe haven for cybercriminals in exchange for those criminals being ‘on-call’ to work for the benefit of the state, here to feed the Chinese Communist party’s insatiable hunger for American and other non-Chinese companies’ hard-earned intellectual property, including COVID-19 research,” Assistant Attorney General for National Securi…

Read more
  • 0